The Directors of Healius Limited announced the appointment of Professor John Mattick AO FAA FTSE FAHMS FRSN HonFRCPA GAICD as an independent Non-executive Director of Healius, to take effect on 31 March 2022. John Mattick is currently SHARP Professor of RNA Biology at UNSW Sydney. He was previously Chief Executive of Genomics England (2018-2019), and Director of the Garvan Institute of Medical Research in Sydney (2012-2018), where he established one of the first HiSeq X10 sequencing and clinically accredited genome analysis facilities.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.255 AUD | -0.40% | -1.95% | -23.24% |
14/05 | Healius Refinances Debt Facility to March 2027 | MT |
06/03 | Morgan Stanley Adjusts Healius’ Price Target to AU$1 From AU$1.30, Keeps at Underweight | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.24% | 612M | |
-17.05% | 8.55B | |
+65.23% | 4.24B | |
-1.63% | 2.53B | |
-9.81% | 2.44B | |
-41.76% | 2.35B | |
-8.53% | 1.89B | |
-19.29% | 1.55B | |
-39.61% | 1.23B | |
+9.68% | 1.13B |
- Stock Market
- Equities
- HLS Stock
- News Healius Limited
- Healius Limited Announces Appointment of John Mattick as Non-Executive Director